{"id":3533,"date":"2017-09-02T00:00:00","date_gmt":"2021-03-19T03:10:09","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=3533"},"modified":"2021-03-19T11:10:09","modified_gmt":"2021-03-19T03:10:09","slug":"eisai-china-listed-in-2016-china-top-100-pharmaceutical-companies","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2017\/09\/02\/eisai-china-listed-in-2016-china-top-100-pharmaceutical-companies\/","title":{"rendered":"Eisai (China) Listed in 2016 China Top 100 Pharmaceutical Companies"},"content":{"rendered":"<p style=\"font-weight: 400;\">Following the 101<sup>st<\/sup>\u00a0place in 2014 and the 97<sup>th<\/sup>\u00a0place in 2015, Eisai China Inc., harvested the 92<sup>nd<\/sup>\u00a0place in the 2016 China Top 100 Pharmaceutical Enterprises List announced by China National Pharmaceutical Industry Information Center. Mr. Zhang Jiekui, Senior Director of Policy Administration of Eisai China Inc., accepted the award on behalf of the company.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.eisai.com.cn\/userfiles\/%E5%A5%96(2).jpg\" alt=\"\" width=\"500\" height=\"375\" \/><span lang=\"EN-US\"><br \/>\n<\/span><span lang=\"EN-US\"><b>Medal won by Eisai China Inc.<\/b><\/span><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p style=\"font-weight: 400;\"><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.eisai.com.cn\/userfiles\/%E7%99%BE%E5%BC%BA(2).jpg\" alt=\"\" width=\"500\" height=\"334\" \/><br \/>\n<\/span><span lang=\"EN-US\"><b>Scene of the awarding ceremony<\/b><\/span><\/p>\n<p><span style=\"font-weight: 400;\">During more than 20 years\u2018 industrious endeavors, Eisai\u2019s staff always sticks to the corporate philosophy to &#8220;give first thought to patients and their families, and to increasing the benefits health care provides&#8221;, continuously brings in high-quality pharmaceutical products, proactively expands and innovates the business models, roots in China and serves Chinese patients and their families. Along with the fast development in China market, led by the management team headed by the President, Mr. Kaneko Norio, and the General Manager, Ms. Feng Yanhui, Eisai\u2018s staff follows the core principles of\u00a0<em>&#8220;<\/em><em>hhc<\/em>, innovation, access, autonomy&#8221;, adheres strictly to the Compliance, and continuously carries out tasks, such as talent development, structure optimization, cost control, efficiency improvement, innovation encouragement and etc. Every Eisai\u2019s employee spends at least 1% of their working time to contact the patients and profoundly feel their sufferings. Eisai is endeavoring to make itself a respectable &#8220;<em>hhc<\/em>&#8221; company in China.<\/p>\n<p><\/span><\/p>\n<p style=\"font-weight: 400;\">Eisai has invested 230 million US dollars in total in China and established entities including Eisai China Holdings Ltd., Eisai (Suzhou) Trading Co., Ltd., Eisai (Liaoning) Pharmaceutical Co., Ltd., and etc., with registered capital of 78.54 million US dollars, nearly 2,000 employees and creating value worth over RMB 3 billion yuan every year. China region has become one of Eisai Group\u2018s global Top 5 independent regions and contributes 8% to the group\u2019s global sales, ranking the 3<sup>rd\u00a0<\/sup>place, just following Japan and the US market. Eisai kept two-digit growth in 2014, 2015 and 2016, and has been the top 1<sup>st<\/sup>\u00a0Japanese pharmaceutical company in China for nearly 10 successive years.<\/p>\n<p style=\"font-weight: 400;\">Eisai has identified neurology and oncology as important areas, and focus on marketing campaigns in 4,800 hospitals in over 100 cities with population of more than one million. In the future, Eisai will further strengthen its strategic production pipelines, penetrate into the lower market, bring in more high-quality drugs in the central neurology and oncology areas, and continuously provide high-quality generic drugs through Eisai (Liaoning) Pharmaceutical Co. Ltd. to better satisfy the needs of Chinese patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following the 101st\u00a0place in 2014 and the 97th\u00a0place in 2015, Eisai China Inc., harvested the 92nd\u00a0place in the 2016 China Top 100 Pharmaceutical Enterprises List announced by China National Pharmaceutical Industry Information Center. Mr. Zhang Jiekui, Senior Director of Policy Administration of Eisai China Inc., accepted the award on behalf of the company.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-3533","post","type-post","status-publish","format-standard","hentry","category-news-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3533"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=3533"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3533\/revisions"}],"predecessor-version":[{"id":3535,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3533\/revisions\/3535"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=3533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=3533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=3533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}